Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

The pharmacology of lxr

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Michael, L. F.
  • Schkeryantz, J. M.
  • Burris, Thomas

publication date

  • 2005

journal

  • Mini-Reviews in Medicinal Chemistry  Journal

abstract

  • Liver X receptors (LXRs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Two LXRs (LXRalpha and LXRbeta) were initially characterized as orphan members of this superfamily with disparate patterns of tissue expression. These two receptors later were recognized as sterol-responsive with the ability to directly bind several oxysterol metabolites. Many LXR target genes have been identified that implicate these receptors in a variety of physiological processes including cholesterol transport and metabolism, glucose metabolism, and inflammation. Synthetic LXR ligands have been designed with the potential to treat disorders such as atherosclerosis and diabetes. In this review, we describe the potential utility of LXR ligands in the treatment of disease.

subject areas

  • Animals
  • Antimetabolites
  • Atherosclerosis
  • Central Nervous System Diseases
  • Cholesterol
  • DNA-Binding Proteins
  • Diabetes Mellitus
  • Glucose
  • Humans
  • Inflammation
  • Ligands
  • Orphan Nuclear Receptors
  • Receptors, Cytoplasmic and Nuclear
  • Structure-Activity Relationship
  • Transcription Factors
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1389-5575

Digital Object Identifier (DOI)

  • 10.2174/1389557054553767

PubMed ID

  • 16101409
scroll to property group menus

Additional Document Info

start page

  • 729

end page

  • 740

volume

  • 5

issue

  • 8

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support